CEACAM5 and neoplasm: In support of this, QoL impairment in colorectal liver metastasis (CLM) patients has been shown to correlate more closely with extent of immune activation than with liver metastasis volume or the serum level of the tumour marker carcinoembryonic antigen (CEA) (Allen-Mersh et al, 1998).